BR100 Decreased By (-0.09%)
BR30 Decreased By (-0.08%)
KSE100 Increased By (0.02%)
KSE30 Decreased By (-0.02%)
AGHA 7.72 Decreased By ▼ -0.09 (-1.15%)
BECO 5.19 Decreased By ▼ -0.02 (-0.38%)
BML 57.50 No Change ▼ 0.00 (0%)
BOP 33.90 Decreased By ▼ -0.13 (-0.38%)
CNERGY 9.96 No Change ▼ 0.00 (0%)
CSIL 5.32 Increased By ▲ 0.01 (0.19%)
FCCL 54.50 Decreased By ▼ -0.20 (-0.37%)
FFL 16.74 Increased By ▲ 0.05 (0.3%)
FNEL 1.25 Increased By ▲ 0.02 (1.63%)
KEL 7.36 Decreased By ▼ -0.04 (-0.54%)
KOSM 5.71 Decreased By ▼ -0.06 (-1.04%)
LOTCHEM 29.19 Decreased By ▼ -0.13 (-0.44%)
MLCF 93.80 Decreased By ▼ -0.56 (-0.59%)
NBP 203.49 Increased By ▲ 0.44 (0.22%)
NCPL 56.84 Decreased By ▼ -0.16 (-0.28%)
NPL 67.61 Decreased By ▼ -0.09 (-0.13%)
OGDC 316.10 Increased By ▲ 0.26 (0.08%)
PACE 10.68 Increased By ▲ 0.04 (0.38%)
PAEL 43.20 No Change ▼ 0.00 (0%)
PIBTL 16.70 Decreased By ▼ -0.04 (-0.24%)
PPL 218.68 Decreased By ▼ -1.10 (-0.5%)
PRL 49.86 Increased By ▲ 0.67 (1.36%)
PTC 71.00 Increased By ▲ 0.47 (0.67%)
SSGC 27.99 Decreased By ▼ -0.26 (-0.92%)
TBL 9.82 Decreased By ▼ -0.04 (-0.41%)
TELE 8.79 No Change ▼ 0.00 (0%)
TPL 18.24 No Change ▼ 0.00 (0%)
TPLP 13.42 Increased By ▲ 0.15 (1.13%)
TREET 22.70 Decreased By ▼ -0.02 (-0.09%)
TRG 60.51 Increased By ▲ 0.37 (0.62%)
Business & Finance

Russia's Sputnik V developers to sue Brazilian regulator for 'false information' about their vaccine

  • The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.
  • A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.
Published Updated
By

MOSCOW: Russian developers of the Sputnik V vaccine against COVID-19 said on Thursday that they were suing Brazilian regulator Anvisa for defamation, accusing it of having knowingly spread false information without testing their product.

The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.

A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.

Sputnik V's official Twitter account on Thursday cited a Brazilian media story citing the same expert as saying that no tests had been carried out to test the Brazilian theory.

"Following the admission of Brazilian regulator Anvisa that it did not test Sputnik V vaccine, Sputnik V is undertaking a legal defamation proceeding in Brazil against Anvisa for knowingly spreading false and inaccurate information," it said.

"Anvisa made incorrect and misleading statements without having tested the actual Sputnik V vaccine."

Comments

Comments are closed for this article.